What is the latest NATCOPHARM stock price?
The latest stored price for NATCOPHARM is Rs 785.75 as of 2026-11-02.
gimli
NATCOPHARM stock AI analysis
NATCOPHARM Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
NATCO PHARMA LTD. is a small-cap stock in Healthcare. This Gimli page shows the latest available NATCOPHARM price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹785.75
1W return
-0.56%
1M return
-4.33%
3M return
-14.31%
6M return
-28.29%
1Y return
-4.17%
Market cap
₹14,073.56 cr
PE
12.30
PB
1.53
ROE
+13.60%
ROCE
+12.91%
RSI
40.00
Turnover
₹15.79 cr
Why it can matter in screens
- Momentum: NATCOPHARM is below 50DMA, below 200DMA; RSI is 40.00.
- Returns: 1D +0.43%, 1W -0.56%, 1M -4.33%, 3M -14.31%, 1Y -4.17%.
- Trend levels: 52W high ₹1,014.00, 52W low ₹773.60, off high -22.51%.
- Liquidity: latest turnover is ₹15.79 cr; volume vs 20D is +0.46%.
- Valuation/profitability: PE 12.30, PB 1.53, ROE +13.60%, ROCE +12.91%.
- Growth: 3Y sales CAGR +14.78%, 3Y profit CAGR +25.63%.
Quick Answers
Is NATCOPHARM above its 50DMA and 200DMA?
NATCOPHARM is below 50DMA, below 200DMA. The latest 50DMA is 820.46 and the latest 200DMA is 929.10.
What are NATCOPHARM PE, ROE and ROCE?
NATCOPHARM has PE 12.30, ROE +13.60%, and ROCE +12.91% in Gimli's latest available snapshot.
How has NATCOPHARM performed recently?
NATCOPHARM has returned -4.33% over 1 month, -14.31% over 3 months, and -4.17% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 735.20 cr | 245.70 cr | 206.50 cr | 11.53 |
| 2026-03-31 | 739.10 cr | 205.40 cr | 267.90 cr | 14.96 |
| 2025-12-31 | 647.30 cr | 216.80 cr | 151.50 cr | 8.46 |
| 2025-09-30 | 1,363.00 cr | 679.20 cr | 518.40 cr | 28.94 |
| 2025-06-30 | 1,328.90 cr | 632.70 cr | 480.70 cr | 26.84 |
| 2025-03-31 | 1,221.00 cr | 614.40 cr | 406.60 cr | 22.70 |
| 2024-12-31 | 474.80 cr | 215.10 cr | 133.00 cr | 7.43 |
| 2024-09-30 | 1,371.10 cr | 868.10 cr | n/a | 37.81 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 4,078.30 cr | 1,734.10 cr | 1,418.50 cr | 79.20 |
| 2025-03-31 | 4,429.50 cr | 2,550.50 cr | 1,885.40 cr | 105.26 |
| 2024-03-31 | 3,978.80 cr | 1,872.30 cr | 1,388.30 cr | 77.34 |
| 2023-03-31 | 2,696.90 cr | 1,035.20 cr | 715.30 cr | 39.18 |
| 2022-03-31 | 1,862.40 cr | 358.00 cr | 139.10 cr | 9.32 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 11,073.70 cr | 198.90 cr | 713.90 cr | 9,221.10 cr |
| 2025-03-31 | 8,630.80 cr | 120.00 cr | 279.40 cr | 7,612.30 cr |
| 2024-03-31 | 6,906.30 cr | 70.40 cr | 371.20 cr | 5,853.10 cr |
| 2023-03-31 | 5,657.40 cr | 131.90 cr | 176.10 cr | 4,873.80 cr |
| 2022-03-31 | 5,109.10 cr | 111.10 cr | 432.00 cr | 4,263.60 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,768.30 cr | 1,377.20 cr | n/a |
| 2025-03-31 | 1,696.80 cr | 1,185.20 cr | n/a |
| 2024-03-31 | 1,211.60 cr | 852.90 cr | n/a |
| 2023-03-31 | 849.10 cr | 643.50 cr | n/a |
| 2022-03-31 | 46.50 cr | -196.20 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +49.42% | +16.99% | +5.62% | +1.92% | +27.97% | +0.00% |
| 2026-03-31 | +49.42% | +17.37% | +5.46% | +1.72% | +27.75% | +0.00% |
| 2025-12-31 | +49.48% | +15.16% | +5.39% | +1.60% | +29.96% | +0.00% |
| 2025-09-30 | +49.48% | +14.09% | +5.87% | +2.20% | +30.56% | +0.00% |
| 2025-06-30 | +49.56% | +15.51% | +5.82% | +2.11% | +29.11% | +0.00% |
| 2025-03-31 | +49.56% | +17.49% | +5.65% | +1.85% | +27.29% | +0.00% |
| 2024-12-31 | +49.62% | +17.94% | +5.57% | +1.92% | +26.87% | +0.00% |
| 2024-09-30 | +49.62% | +17.51% | +6.75% | +2.37% | +26.12% | +0.00% |
| 2024-06-30 | +49.71% | +17.45% | +7.87% | +2.67% | +24.97% | +0.00% |
| 2024-03-31 | +49.71% | +16.14% | +9.70% | +4.08% | +24.45% | +0.00% |
| 2023-12-31 | +49.71% | +13.72% | +11.25% | +5.20% | +25.32% | +0.00% |
| 2023-09-30 | +49.71% | +12.82% | +14.01% | +7.65% | +23.46% | +0.00% |
| 2023-06-30 | +49.76% | +11.02% | +15.15% | +9.45% | +24.07% | +0.00% |
| 2023-03-31 | +48.84% | +11.91% | +15.38% | +8.50% | +23.87% | +0.00% |
| 2022-12-31 | +48.82% | +11.72% | +14.93% | +8.18% | +24.53% | +0.00% |
| 2022-09-30 | +48.80% | +11.67% | +14.31% | +7.63% | +25.23% | +0.00% |
| 2022-06-30 | +48.80% | +0.00% | +26.95% | n/a | n/a | +0.00% |
| 2022-03-31 | +48.81% | +0.00% | +28.09% | n/a | n/a | +0.00% |
| 2021-12-31 | +48.86% | +0.00% | +30.34% | n/a | n/a | n/a |
| 2021-09-30 | +48.87% | +0.00% | +30.31% | n/a | n/a | n/a |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 424,682.29 cr | 35.055325 | +15.50% | +4.69% |
| DIVISLAB | DIVI S LABORATORIES LTD | 264,021.80 cr | 90.604597 | +18.37% | +47.60% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 155,515.66 cr | 73.218296 | +16.87% | +29.07% |
| LAURUSLABS | LAURUS LABS LIMITED | 126,758.33 cr | 116.063114 | +21.77% | +146.21% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 124,823.33 cr | 27.816403 | +16.04% | +27.30% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 121,627.48 cr | 57.744613 | +22.62% | +10.13% |
| CIPLA | CIPLA LTD | 112,041.93 cr | 38.674756 | +8.80% | -7.61% |
| DRREDDY | DR. REDDY S LABORATORIES | 111,734.22 cr | 39.916484 | +7.80% | +12.06% |
Try these prompts
- Analyze NATCO PHARMA. with valuation, momentum and industry peers
- Compare NATCOPHARM with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare NATCOPHARM with other Healthcare stocks
Data snapshot: 2026-11-02. Not investment advice.